title: Enhanced cellular delivery of idarubicin by surface modification of propyl starch nanoparticles employing pteroic acid conjugated polyvinyl alcohol.
abstract: Enhanced intracellular internalization of the anti-cancer active idarubicin (IDA) was achieved through appropriate surface modification of IDA loaded propyl starch nanoparticles. This was conducted by synthesizing pteroic acid modified polyvinyl alcohol (ptPVA) and employing this stabilizer for formulating the said nanoparticles. Pteroic acid attached at the nanoparticles improved the surface protein adsorption of the nanoparticle, a condition which the nanoparticles would largely experience in vitro and in vivo and hence improve their cellular internalization. Spherical, homogenous IDA nanoparticles (214 ± 5 nm) with surface modified by ptPVA were formulated using the solvent emulsification-diffusion technique. The encapsulation efficiency and drug loading amounted around 85%. In vitro release studies indicated a controlled release of IDA. Safety and efficacy of the nanoparticles was confirmed by suitable cellular cytotoxicity assays. Protein binding studies indicated a higher adsorption of the model protein on nanoparticles formulated with ptPVA as compared to PVA. Cellular uptake studies by confocal laser scanning microscopy revealed a higher cellular uptake of ptPVA stabilized nanoparticles thus confirming the proposed hypothesis of higher protein adsorption being responsible for higher cellular internalization.
authors: Department of Biopharmaceutics and Pharmaceutical Technology, Campus A4 1, Saarland, University, Saarbrücken, Germany.
authors: Ratnesh
authors: R
authors: Jain
authors: Prajakta
authors: P
authors: Dandekar
authors: Brigitta
authors: B
authors: Loretz
authors: Ana
authors: A
authors: Melero
authors: Thomas
authors: T
authors: Stauner
authors: Gerhard
authors: G
authors: Wenz
authors: Marcus
authors: M
authors: Koch
authors: Claus-Michael
authors: CM
authors: Lehr
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000327:Adsorption; D000903:Antibiotics, Antineoplastic / Q000737:chemistry / Q000378:metabolism*; D018938:Caco-2 Cells; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D003110:Colonic Neoplasms / Q000378:metabolism / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D004339:Drug Compounding; D004355:Drug Stability; D019073:HT29 Cells; D006801:Humans; D015255:Idarubicin / Q000737:chemistry / Q000378:metabolism*; D007700:Kinetics; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology; D018613:Microscopy, Confocal; D053758:Nanoparticles; D036103:Nanotechnology; D010316:Particle Size; D011142:Polyvinyl Alcohol / Q000031:analogs & derivatives / Q000138:chemical synthesis*; D011485:Protein Binding; D011622:Pterins / Q000737:chemistry*; D012995:Solubility; D013213:Starch / Q000031:analogs & derivatives / Q000138:chemical synthesis*; D013501:Surface-Active Agents / Q000138:chemical synthesis*; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D011622:Pterins; D013501:Surface-Active Agents; C005584:pteroic acid; D011142:Polyvinyl Alcohol; D013213:Starch; D015255:Idarubicin